Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis.

摘要: Method 4022 patients (>=12 years old) were randomized into 4, 14-day double-blind, placebo-controlled SAR trials to receive MP29-02*, AZE, FP or placebo nasal sprays (all given as 1 spray/nostril bid). 612 a 1-year, open-label, active-controlled, parallel-group chronic rhinitis trial MP29-02* (1 bid) spray (2 sprays/nostril qd). For all studies the total daily dose of AZE and was 548 g 200 μg respectively. Safety assessed by incidence, type, severity adverse events, vital signs examination.